chevron_leftBack
As of 14 June 2026, Zentalis Pharmaceuticals, Inc. has a market cap of $280.89M USD, ranking #18980 globally and #3154 in the United States.
It ranks #1710 in the Healthcare sector, and #326 in the Biotechnology industry.
Key Stats
Market Cap
$280.89MUSD
Enterprise Value
$76.34MUSD
EBITDA (TTM)
-$140.14MUSD
Net Income (TTM)
-$137.06MUSD
PB Ratio
1.3
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Biotechnology
CEO
Julie Eastland
open_in_new
Employees
106
Founded
2014
IPO
03 Apr 2020
Website
zentalis.com
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| -2.2% | -0.1% | 90% | 56% | 133% | 181% |
News
Loading...
ZNTL Analyst Forecasts
Loading...
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
ZNTL
Zentalis Pharmaceuticals Inc Ordinary Shares
ISIN: US98943L1070
Shares Out.:
Shares Outstanding:
71.186M1
Shares Float:
45.985M2
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
NQ:
NASDAQ:
BA:
Barron's:
MS:
Morningstar:
|
3.96 USD |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About Zentalis Pharmaceuticals, Inc.
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States. It develops azenosertib, which is in a Phase 3 clinical trial for the treatment of ovarian cancer and other tumor types. The company also develops ZN-c3-001, a phase 1 study that evaluated azenosertib monotherapy in solid tumors; and MAMMOTH (ZN-c3-006) is a Phase 1/2 clinical trial of azenosertib in patients with PARP-inhibitor resistant ovarian cancer. It has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC. Zentalis Pharmaceuticals, Inc. was incorporated in 2014 and is based in San Diego, California.
Similar Companies
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
NASDAQ: AMGN
|
$182.42B
65K%
|
23.9
|
|
NASDAQ: GILD
|
$159.92B
57K%
|
19.0
|
|
NASDAQ: NTRA
|
$27.6B
10K%
|
-
|
|
NYSE: IQV
|
$26.3B
9K%
|
20.0
|
|
NASDAQ: UTHR
|
$25.03B
9K%
|
20.4
|
|
NASDAQ: MRNA
|
$18.13B
6K%
|
-
|
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
EBR: ARGX
|
$47.84B
17K%
41.39B EUR
|
39.9
|
|
KRX: 207940
|
$44.84B
16K%
68.19T KRW
|
35.5
|
|
ASX: CSL
|
$42.36B
15K%
60.27B AUD
|
29.3
|
|
SIX: LONN
|
$42.3B
15K%
33.71B CHF
|
37.2
|
|
KRX: 068270
|
$28.11B
10K%
42.76T KRW
|
43.8
|
|
NASDAQ: BNTX
|
$25.69B
9K%
|
-
|
chevron_leftBack